Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. (24th April 2015)

• Record Type: Journal Article
• Authors: Campillo-Gimenez, Laure; Assoumou, Lambert; Valantin, Marc-Antoine; Pajanirassa, Priyadharshini; Villemonteix, Juliette; Soulié, Cathia; Marcelin, Anne-Geneviève; Costagliola, Dominique; Capeau, Jacqueline; Autran, Brigitte; Katlama, Christine; Guihot, Amélie
• Is Part Of: AIDS. Volume 29:Number 7(2015)
• Publication Date: 2015-04-24
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000000626
• Languages: English
• ISSNs: 0269-9370

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4⁺/CD8⁺ ratio decreased and the CD8⁺ T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.</p> </sec> </abstract>